Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy.

Authors:
Sun Y; Guo Y; Liu X; Liu J; Sun H and 5 more

Journal:
Theranostics

Publication Year: 2023

DOI:
10.7150/thno.87340

PMCID:
PMC10614684

PMID:
37908720

Journal Information

Full Title: Theranostics

Abbreviation: Theranostics

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Diagnostic Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability statement all rna-seq raw data and processed read counts have been submitted to gene expression omnibus (gse243980) metabolomics data of bacteria have been deposited in the embl-ebi under accession code mtbls8667. data availability statement all rna-seq raw data and processed read counts have been submitted to gene expression omnibus (gse243980"

Code Sharing
Evidence found in paper:

"Competing Interests: The authors have declared that no competing interest exists."

Evidence found in paper:

"This work was supported by the National Natural Science Foundation of China (82273831, 82001753, 82311540161, 82171469, and 81960556), Hunan Natural Science Foundation (2023JJ20022), and Fundamental Research Funds for the Central Universities, China (541109030048)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025